Beta-Catenin & Hepatocellular Cancer: From bench to Bedside

In this CME, Satdarshan (Paul) S. Monga, MD discusses how to explain the molecular subclasses of hepatocellular cancers (HCCs) in particular the subclass driven by CTNNB1 mutations leading to Wnt-beta-catenin activation (around 35-40% of all HCCs), describe metabolic addiction of CTNNB1-mutated HCC that is a therapeutic vulnerability and being investigated in a clinical trial, and implement the management of CTNNB1-mutated HCC by direct targeting of beta-catenin using siRNA and lipid nanoparticle impacting tumor cell survival and immune microenvironment as a precision medicine clinical trial.

Educational Objectives 

Upon completion of this activity, participants should be able to:

• Explain the molecular subclasses of hepatocellular cancers (HCCs) in particular the subclass driven by CTNNB1 mutations leading to Wnt-beta-catenin activation (around 35-40% of all HCCs)
• Describe metabolic addiction of CTNNB1-mutated HCC that is a therapeutic vulnerability and being investigated in a clinical trial
• Implement the management of CTNNB1-mutated HCC by direct targeting of beta-catenin using siRNA and lipid nanoparticle impacting tumor cell survival and immune microenvironment as a precision medicine clinical trial

Disclosures:

All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships for the individuals listed below have been mitigated. 

Dr. Satdarshan (Paul) S. Monga receives; 

• Grant/Research Support: Revolution Medicine, Alnylam
• Consultant: lnylan, UbiquiTx,

Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of x.xx AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page.

Release Date: 10/19/2026 | Last Modified On: 10/19/2026 | Expires: 10/19/2027